Abstract:Annexin IV (ANXA4) is highly expressed in ovarian clear cell carcinoma (OCCC); however, its underlying molecular mechanism in OCCC remains unknown. The present study aimed to identify the molecule that ANXA4 may act on and to determine its underlying molecular mechanism. Immunohistochemistry, co-immunoprecipitation and western blotting were performed to detect the expression and interaction of ANXA4, and its associated proteins. Furthermore, MTT assay, flow cytometry, western blotting and gene expression profile enrichment analysis were performed to identify the potential role and molecular mechanism of ANXA4 in OCCC. The results demonstrated that ANXA4 and nuclear factor-kappa-light-chain-enhancer of activated B cells (NF-kappa B) p50 nuclear expression levels were significantly higher in OCCC tissues compared with other subtypes of ovarian cancer, such as serous and mucinous. In addition, a significantly positive correlation was observed between ANXA4 and NF-kappa B p50 expression in OCCC; however, the expression levels of mutant p53 and ANXA4 were negatively correlated in a linear manner. These results suggest that ANXA4 and NF-kappa B p50 may be potential independent risk factors for poor prognosis. ANXA4 and NF-kappa B p50 were demonstrated to interact and their expression was co-localized. The cBioPortal database was used to construct a protein-protein interaction network between ANXA4, NF-kappa B p50 and p53, and functional pathway analysis indicated that the genes were predominantly enriched in the cell cycle and during apoptosis. Transfection of the ANXA4 gene increased the expression of NF-kappa B p50, as well as its downstream targets, Cyclin D1 and B-cell lymphoma-2 (Bcl-2). Furthermore, transfection of the ANXA4 gene increased proliferation and decreased apoptosis of OCCC cells. Treatment with the NF-kappa B inhibitor, BAY 11-7082, decreased Cyclin D1 and Bcl-2 expression levels. Collectively, the results of the present study suggest that wild p53 activates ANXA4 transcription, promotes its expression and enhances NF-kappa B p50 and ANXA4 interaction. This in turn activates the NF-kappa B signaling pathway, promotes cell cycle progression and inhibits apoptosis, thus contributing to the malignant progression of OCCC. Thus, ANXA4 and NF-kappa B p50 may be used as prognostic biomarkers, and may be molecular therapeutic targets in OCCC.

P62 Aggregates Mediated Caspase 8 Activation is Responsible for Progression of Ovarian Cancer

XIAP Facilitates Breast and Colon Carcinoma Growth Via Promotion of P62 Depletion Through Ubiquitination-Dependent Proteasomal Degradation

P62/sqstm1 Involved in Cisplatin Resistance in Human Ovarian Cancer Cells by Clearing Ubiquitinated Proteins.

p62 Promotes the Mitochondrial Localization of p53 through Its UBA Domain and Participates in Regulating the Sensitivity of Ovarian Cancer Cells to Cisplatin

An Alternatively Spliced P62 Isoform Confers Resistance to Chemotherapy in Breast Cancer

An Experimentally Induced Mutation in the UBA Domain of p62 Changes the Sensitivity of Cisplatin by Up-Regulating HK2 Localisation on the Mitochondria and Increasing Mitophagy in A2780 Ovarian Cancer Cells

Insight into the Role of P62 in the Cisplatin Resistant Mechanisms of Ovarian Cancer

Cytoplasmic SQSTM1/ P62 Accumulation Predicates a Poor Prognosis in Patients with Malignant Tumor.

P62/sqstm1 As an Oncotarget Mediates Cisplatin Resistance Through Activating RIP1‐NF‐κB Pathway in Human Ovarian Cancer Cells

P62/Sqstm1 is Involved in Cisplatin Resistance in Human Ovarian Cancer Cells Via the Keap1-Nrf2-Are System

High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer

Akt-Mediated Cisplatin Resistance in Ovarian Cancer: Modulation of p53 Action on Caspase-Dependent Mitochondrial Death Pathway

Autophagic Regulation of P62 is Critical for Cancer Therapy

SQSTM1/p62 in Intrahepatic Cholangiocarcinoma Promotes Tumor Progression Via Epithelial–mesenchymal Transition and Mitochondrial Function Maintenance

p53 and ANXA4/NF-B p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma

Triggering Apoptosis by Oroxylin A Through Caspase-8 Activation and P62/sqstm1 Proteolysis

SQSTM1/p62 regulate breast cancer progression and metastasis by inducing cell cycle arrest and regulating immune cell infiltration

Zinc finger domain of p62/SQSTM1 is involved in the necroptosis of human cisplatin‑resistant ovarian cancer cells treated with sulfasalazine

SQSTM1/p62 promotes the progression of gastric cancer through epithelial-mesenchymal transition

The P53 Upregulated Modulator of Apoptosis (PUMA) Chemosensitizes Intrinsically Resistant Ovarian Cancer Cells to Cisplatin by Lowering the Threshold Set by Bcl-x(L) and Mcl-1.

Overexpression of P62 is Associated with Poor Prognosis and Aggressive Phenotypes in Osteosarcoma